 CAMBRIDGE, Mass., April 2, 2021 PRNewswire -- Akebia Therapeutics, Inc. Nasdaq: AKBA, a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 19 newly-hired employees options to purchase an aggregate of 131,000 shares of Akebias common stock on March 31, 2021, as inducements material to each such employees entering into employment with Akebia. 